person("Bandur","Dragos", role = c("aut", "cre"), email = "dbandur@sympatico.ca")
Updates values within csv format data files using a custom, User-built
csv format lookup file. Based on 'data.table' package.
magrittr, knitr, rmarkdown, carData, testthat (>= 3.0.0),
checkmate, tinytest

knitr, kableExtra, rmarkdown, carData, testthat (>= 3.0.0),
checkmate, tinytest

Average Bioequivalence with Expanding Limits (ABEL)
c(person("Helmut", "Schütz",
role = c("aut", "cre"),
email = "helmut.schuetz@bebac.at",
comment = c(ORCID = "0000-0002-1167-7880")),
person("Michael", "Tomashevskiy",
role = "ctb",
email = "mittyright@yandex.ru"),
person("Detlew", "Labes",
role = "ctb",
email = "DetlewLabes@gmx.de",
comment = c(ORCID = "0000-0003-2169-426X")))
Helmut Schütz [aut, cre] (<https://orcid.org/0000-0002-1167-7880>),
Michael Tomashevskiy [ctb],
Detlew Labes [ctb] (<https://orcid.org/0000-0003-2169-426X>)
readxl (>= 1.0.0), PowerTOST (>= 1.3.3), lmerTest, nlme,
pbkrtest, graphics, grDevices
Performs comparative bioavailability-calculations for the
EMA's Average Bioequivalence with Expanding Limits (ABEL).
Implemented are 'Method A' and 'Method B', detection of
outliers. If the design allows, assessment of the empiric
Type I Error and iteratively adjusting alpha to control the
consumer risk.
Average Bioequivalence (ABE) - optionally with tighter
(EMA: NTIDs) or wider limits (GCC: Cmax) - is implemented
as well.

Performs comparative bioavailability-calculations for the EMA's Average Bioequivalence
with Expanding Limits (ABEL). Implemented are 'Method A' and 'Method B', detection of outliers.
If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to
control the consumer risk.
Average Bioequivalence (ABE) - optionally with tighter (EMA: NTIDs) or wider limits (GCC: Cmax) -
is implemented as well.

Performs comparative bioavailability calculations for the EMA's Average Bioequivalence
with Expanding Limits (ABEL). Implemented are 'Method A' and 'Method B', detection of outliers.
If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to
control the consumer risk.
Average Bioequivalence (ABE) - optionally with tighter (EMA: NTIDs) or wider limits (GCC: Cmax) -
is implemented as well.